From Pymnts · PYMNTS · · 1m 20s
Anthropic Buys Biotech to Test AI Drug Making
Anthropic acquires Mithril Medicine to prove Claude can develop drugs in under 18 months.
In brief
Anthropic acquires Mithril Medicine to prove Claude can develop drugs in under 18 months. Anthropic bought Mithril Medicine, a one-person biotech startup, to test if Claude can create muscle dystrophy treatments in under 18 months. Originally reported by Pymnts.
Anthropic Acquires Mithril Medicine
Anthropic bought Mithril Medicine, a biotech startup with one full-time employee, to test if Claude can create muscle dystrophy treatments in under 18 months.
Cody Tranbarger Uses Claude
Founder Cody Tranbarger used Claude to organize contracts, logistics and experiments across 11 external labs and took one candidate from idea to promising results in mice in under 18 months.
Mithril’s Drug Progress
Mithril’s lead antibody has been tested only in mice and remains mostly preclinical, with potential human trials by late 2028.
OpenAI Buys Orchestra Bio
OpenAI agreed to buy Orchestra Bio, a platform where scientists hand study monitoring and timeline tracking to AI agents.
Orchestra Tracks Drug Programs
Orchestra’s agents work out which trial dates slip and what the team can do when a manufacturing batch fails.
Enveda Cuts Review Time
Enveda’s Claude tool cut review time from almost 26 hours to just under three hours, an 89% reduction.
Healthcare AI Spending
84% of healthcare firms expect to increase AI spending over the next 12 months according to a PYMNTS Intelligence report.
At a glance
Anthropic bought Mithril Medicine, a one-person biotech startup, to test if Claude can create muscle dystrophy treatments in under 18 months.
